INIS 10-Q
Radnostix Inc (INIS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from _____________ to _______________
Commission file number:
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. ý
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ¨ | Accelerated filer ¨ |
|
|
Smaller reporting company
|
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). ¨ Yes ý
As of November 8, 2021, the number of shares of common stock, $0.01 par value, outstanding was shares.
1
INTERNATIONAL ISOTOPES INC.
Form 10-Q
For The Quarter Ended September 30, 2021
TABLE OF CONTENTS
| Page No. | ||
| PART I – FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements | |
| Unaudited Condensed Consolidated Balance Sheets at September 30, 2021 and December 31, 2020 | 3 | |
| Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 | 4 | |
| Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 | 5 | |
| Unaudited Statement of Reconciliation of Stockholder’s (Deficit) Equity for the Three and Nine Months Ended September 30, 2021 and 2020 | 6 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 8 | |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 18 |
| Item 4. | Controls and Procedures | 28 |
| PART II – OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 28 |
| Item 1A. | Risk Factors | 28 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 28 |
| Item 6. | Exhibits | 29 |
| Signatures | 30 | |
| 2 |
Part I. Financial Information
Item I. Financial Statements
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(unaudited)
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable | ||||||||
| Inventories | ||||||||
| Prepaids and other current assets | ||||||||
| Total current assets | ||||||||
| Long-term assets | ||||||||
| Restricted cash | ||||||||
| Property, plant and equipment, net | ||||||||
| Capitalized lease disposal costs, net | ||||||||
| Financing lease right-of-use asset | ||||||||
| Operating lease right-of-use asset | ||||||||
| Goodwill | ||||||||
| Patents and other intangibles, net | ||||||||
| Total long-term assets | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Unearned revenue | ||||||||
| Current portion of operating lease right-of-use liability | ||||||||
| Current portion of financing lease liability | ||||||||
| Current portion of related party notes payable, net of debt discount | ||||||||
| Current installments of notes payable | ||||||||
| Current portion of mandatorily redeemable preferred stock, net of debt discount | ||||||||
| Total current liabilities | ||||||||
| Long-term liabilities | ||||||||
| Related party notes payable, net of current portion and debt discount | ||||||||
| Notes payable, net of current portion | ||||||||
| Asset retirement obligation | ||||||||
| Financing lease liability, net of current portion | ||||||||
| Operating lease right-of-use liability, net of current portion | ||||||||
| Mandatorily redeemable convertible preferred stock, net of current portion and discount | ||||||||
| Total long-term liabilities | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 8) | ||||||||
| Stockholders' equity | ||||||||
| Common stock, $ par value; shares authorized; and shares issued and outstanding respectively | ||||||||
| Additional paid in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Equity attributable to International Isotopes Inc. stockholders | ||||||||
| Equity attributable to noncontrolling interest | ||||||||
| Total equity | ||||||||
| Total liabilities and stockholders' equity | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
| 3 |
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Operations
Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Sale of product | $ | $ | $ | $ | ||||||||||||
| Cost of product | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating costs and expenses | ||||||||||||||||
| Salaries and contract labor | ||||||||||||||||
| General, administrative and consulting | ||||||||||||||||
| Research and development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Net operating income (loss) | ( | ) | ||||||||||||||
| Other income (expense): | ||||||||||||||||
| Other income | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other (expense) income | ( | ) | ( | ) | ( | ) | ||||||||||
| Net (loss) income | ( | ) | ( | ) | ||||||||||||
| Less income attributable to noncontrolling interest | ||||||||||||||||
| Net (loss) income attributable to International Isotopes Inc. | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Net loss per common share - basic: | $ | $ | $ | $ | ||||||||||||
| Net loss per common share - diluted: | $ | $ | $ | $ | ||||||||||||
| Weighted average common shares outstanding - basic: | ||||||||||||||||
| Weighted average common shares outstanding - diluted: | ||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
4
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine months ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash flows from operating activities | ||||||||
| Net (loss) income | $ | ( | ) | $ | ||||
| Adjustments to reconcile net (loss) income to net Cash provided by operating activities | ||||||||
| Depreciation and amortization | ||||||||
| Accretion of obligation for lease disposal costs | ||||||||
| Accretion of beneficial conversion feature and discount | ||||||||
| Equity based compensation | ||||||||
| Gain on sale of property, plant and equipment | ( | ) | ||||||
| Forgiveness of Paycheck Protection Program Loan | ( | ) | ||||||
| Right-of-use asset amortization | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Inventories | ||||||||
| Prepaids and other current assets | ||||||||
| Accounts payable and accrued liabilities | ( | ) | ( | ) | ||||
| Unearned revenues | ( | ) | ( | ) | ||||
| Net cash provided by operating activities | ||||||||
| Cash flows from investing activities: | ||||||||
| Proceeds from sale of property, plant and equipment | ||||||||
| Purchase of property, plant and equipment | ( | ) | ( | ) | ||||
| Net cash (used in) provided in investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from sale of stock | ||||||||
| Payments on financing lease | ( | ) | ( | ) | ||||
| Distributions to non-controlling interest | ( | ) | ||||||
| Proceeds from the issuance of notes payable | ||||||||
| Principal payments on notes payable | ( | ) | ( | ) | ||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | ( | ) | ||||||
| Cash, cash equivalents, and restricted cash at beginning of period | ||||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow activities: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Supplemental disclosure of noncash financing and investing transactions | ||||||||
| Decrease in accrued interest and increase in equity for conversion of dividends to stock | $ | $ | ||||||
| Increase in operating lease right-of-use asset and right-of-use liability for new lease | $ | $ | ||||||
| Increase in equity and decrease in liability for the conversion of preferred stock | $ | $ | ||||||
| Non-cash increase of capitalized asset retirement obligation for increased funding plan | $ | $ | ||||||
| Decrease in operating lease right-of-use asset and right-of-use liability for disposal of old lease | $ | $ | ||||||
| Increase in financing lease right-of-use asset and right-of-use liability for new lease | $ | $ | ||||||
| Decrease in inventory and decrease in accounts payable for cancellation of DOE contract | $ | $ | ||||||
| Decrease in related party notes payable and increase in equity for amounts allocated to warrants and beneficial conversion feature | $ | $ | ||||||
| Decrease in unearned revenue and increase in notes payable for repayment plan | $ | 146,072 | $ | — | ||||
| Increase in equity and decrease in Non-controlling interest for acquisition of non controlling interest in RadQual and TI Services | $ | $ | ||||||
Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:
| September 30, | September 30, | |||||||
| 2021 | 2020 | |||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash included in long-term assets | ||||||||
| Total cash, cash equivalents, and restricted cash shown in statement of cash flows | $ | $ | ||||||
See accompanying notes to the unaudited condensed consolidated financial statements.
5
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Reconciliation of Stockholders' (Deficit) Equity
Three and Nine Months Ended September 30, 2021
(Unaudited)
| Equity | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| to | Attributable | |||||||||||||||||||||||||||
| Common stock | Additional | Internat'l | to | Total | ||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, January 1, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Stock grant | ( | ) | ||||||||||||||||||||||||||
| Stock in lieu of dividends on convertible preferred C | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Warrant exercise | ( | ) | ||||||||||||||||||||||||||
| Conversion of preferred C stock | ||||||||||||||||||||||||||||
| Conversion of preferred B stock | ||||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Shares issued for purchase of 75.5% of RadQual | ( | ) | ||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | ( | ) | ( | ) | |||||||||||||||||||||||
| Net (loss) income | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Balance, September 30, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Equity | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| to | Attributable | |||||||||||||||||||||||||||
| Common stock | Additional | Internat'l | to | Total | ||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, July 1, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Conversion of preferred C stock | ||||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Shares issued for purchase of 75.5% of RadQual | ( | ) | ||||||||||||||||||||||||||
| Distribution to non-controlling interest | — | ( | ) | ( | ) | |||||||||||||||||||||||
| Net (loss) income | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| Balance, September 30, 2021 | $ | $ | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||
6
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Reconciliation of Stockholders' (Deficit) Equity
Three and Nine Months Ended September 30, 2020
(Unaudited)
| Deficit | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| To | Attributable | |||||||||||||||||||||||||||
| Common stock | Additional | Internat'l | to | Total | ||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, January 1, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Stock grant | ( | ) | ||||||||||||||||||||||||||
| Stock in lieu of dividends on convertible preferred C | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Convertible debentures beneficial conversion feature | — | |||||||||||||||||||||||||||
| Warrants issued with convertible debentures | — | |||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Net income | — | |||||||||||||||||||||||||||
| Balance, September 30, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||||||||||||
| Deficit | ||||||||||||||||||||||||||||
| Attributable | Equity | |||||||||||||||||||||||||||
| To | Attributable | |||||||||||||||||||||||||||
| Common stock | Additional | Internat'l | to | Total | ||||||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Isotopes | Noncontrolling | (Deficit) | ||||||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Shareholders | Interest | Equity | ||||||||||||||||||||||
| Balance, July 1, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||||||||||||
| Shares issued under employee stock purchase plan | ||||||||||||||||||||||||||||
| Shares issued for exercise of employee stock options | ( | ) | ||||||||||||||||||||||||||
| Stock based compensation | — | |||||||||||||||||||||||||||
| Net income | — | |||||||||||||||||||||||||||
| Balance, September 30, 2020 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | ||||||||||||||||||
See accompanying notes to the unaudited condensed consolidated financial statements
7
INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements
September 30, 2021
(1) The Company and Basis of Presentation
International Isotopes Inc. (INIS) was incorporated
in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting
principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly owned
subsidiaries, including RadQual, LLC (RadQual). The unaudited condensed consolidated financial statements also include the accounts of
INIS’s
Nature of Operations – INIS and its subsidiaries (including RadQual) and TI Services manufacture a full range of nuclear medicine calibration and reference standards, generic sodium iodide I-131 drug product, cobalt teletherapy sources, and a varied selection of radiochemicals for medical research, and clinical applications. The Company’s business consists of five business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.
With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s condensed consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.
Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. See Note 4 “RadQual Acquisition” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.
Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three or nine-month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 30, 2021.
Recent Accounting Pronouncements – In August 2020, the Financial Accounting Standards Board issued ASU 2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). The update simplifies accounting related to convertible debt instruments. The standard is effective for fiscal years beginning after December 15, 2023 including interim periods within those fiscal years. INIS is currently evaluating the effect this standard will have on its financial statements.
(2) Current Developments and Liquidity
Business Condition – Since inception,
the Company has incurred substantial losses. During the nine months ended September 30, 2021, the Company reported net loss of $
8
During the nine months ended September 30, 2021, the Company continued its focus on its strongest long-standing core business segments which consist of its radiochemical products, cobalt products, and nuclear medicine standards, and in particular, the pursuit of new business opportunities within those segments.
Additionally, the Company holds a Nuclear Regulatory
Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea
County, New Mexico, where the plant is intended to be constructed.
The Company expects that cash from operations, equity or debt financing, and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.
For the three and nine months ended September 30, 2021, the Company had stock options outstanding, warrants outstanding, outstanding shares of Series B redeemable convertible preferred stock (Series B Preferred Stock), and outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.
For the nine months ended September 30, 2020, the Company had stock options outstanding, warrants outstanding, outstanding shares of Series C Preferred Stock, and outstanding shares of Series B Preferred Stock, each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive. The Company used the treasury stock method in calculating weighted average common shares diluted.
For the three months ended September 30, 2020, the Company had stock options outstanding, warrants outstanding, outstanding shares of Series C redeemable convertible preferred stock, and outstanding shares of Series B redeemable convertible preferred stock, each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive. The Company used the treasury stock method in calculating weighted average common shares diluted.
| 3 Months Ended | 9 Months Ended | |||||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Weighted average common shares outstanding - basic | ||||||||||||||||
| Effects of dilutive shares | ||||||||||||||||
| Stock Options | — | — | ||||||||||||||
| Warrants | — | — | ||||||||||||||
| Weighted average common shares outstanding - diluted | ||||||||||||||||
The table below summarizes common stock equivalents outstanding at September 30, 2021 and 2020:
| September 30, | ||||||||
| 2021 | 2020 | |||||||
| Stock options | ||||||||
| Warrants | ||||||||
| Shares of Series B redeemable convertible preferred stock | ||||||||
| Shares of Series C redeemable convertible preferred stock | ||||||||
9
(4) RadQual Acquisition
On July 8, 2021, the Company
entered into a Membership Interest Purchase Agreement (the Purchase Agreement) with RadQual and the sellers set forth in the Purchase
Agreement, which included the Company’s Chairman of the Board, Chief Executive Officer, former Chairman of the Board, and certain
other stockholders of the Company (collectively, the “Sellers”). Pursuant to the Purchase Agreement, the Company acquired
all of the outstanding membership interests of RadQual not then owned by the Company for an aggregate purchase price of approximately
$
(5) Inventories
Inventories consisted of the following at September 30, 2021 and December 31, 2020:
| September 30, 2021 | December 31, 2020 | |||||||
| Raw materials | $ | $ | ||||||
| Work in process | ||||||||
| Finished goods | ||||||||
| Total inventory | $ | $ | ||||||
Work in process also includes
costs to irradiate cobalt-60 material under a contract with the DOE. This material has been placed in the ATR and the Company made progress
payments to purchase this material. During the second quarter and fourth quarter of 2020, the Company modified its agreement with the
DOE due to delays in delivery of Cobalt material. As a result, the DOE refunded certain payments made by INIS in relation to this material
and INIS stopped paying the scheduled payments for the inventory. At September 30, 2021, and at December 31, 2020, this cobalt target
inventory had a carrying value of $
The Company has contracted
with several customers for the sale of some of this cobalt material and has collected advance payments for project management, up-front
handling, and other production costs from those customers. The advance payments from customers were recorded as unearned revenue which
are recognized in the Company’s condensed consolidated financial statements as cobalt products are completed and shipped. For the
nine months ended September 30, 2021, and 2020, the Company recognized approximately $
(6) Stockholders’ Equity, Options, and Warrants
Employee Stock Purchase Plan
The Company has an employee stock purchase plan pursuant
to which employees of the Company may participate to purchase shares of common stock at a discount. During the nine months ended September
30, 2021, and 2020, the Company issued and shares of common stock, respectively, to employees under the employee stock
purchase plan for proceeds of $
Stock-Based Compensation Plans
2015 Incentive Plan - In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the 2015 Plan), which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 Plan by an additional shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards. At September 30, 2021, there were shares available for issuance under the 2015 Plan.
10
Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).
Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by recognizing compensation expense based on the grant date fair value of the award. Stock option compensation expense is recognized over the vesting period for the award.
| Fixed Options | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value | ||||||||||||
| Outstanding at December 31, 2020 | $ | |||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Expired | ||||||||||||||||
| Forfeited | ( | ) | ||||||||||||||
| Outstanding at September 30, 2021 | $ | |||||||||||||||
| Exercisable at September 30, 2021 | $ | $ | ||||||||||||||
The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $ per share on September 30, 2021, the last trading day of the quarter.
As of September 30, 2021, there was $ of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of years.
Total stock-based compensation expense for the nine months ended September 30, 2021, and 2020 was $ and $ respectively. Total stock-based compensation expense for the three-months ended September 30, 2021, and 2020 was $ and $, respectively.
During the nine months ended September 30, 2021, the Company granted an aggregate of qualified stock options to several of its employees. All options vest over a -year period with the first vesting at the one-year anniversary for all grants and expiration at ten-year anniversary for all grants. The weighted average exercise price for these options was $ per share. The options have a fair value of $ as estimated on the date of issue using the Black-Scholes options pricing model with the following weighted-average assumptions: risk free interest rate of % to %, expected dividend yield rate of %, expected volatility of % to % and an expected life between and years.
In January 2021, qualified stock options were exercised under a cashless exercise. The company withheld shares to satisfy the exercise price and issued shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.
In September 2021, qualified stock options were exercised under a cashless exercise. The company withheld shares to satisfy the exercise price and issued shares of common stock. The options exercised were granted under the 2015 Plan, and, accordingly, there was not any income tax effect in the condensed consolidated financial statements for the year ended December 31, 2021.
Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded fully vested shares of common stock to its Chief Executive Officer in February 2021 under the 2015 Plan. The number of shares awarded was based on a $ stock award using a price of $ per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2021, which was $ per share. The Company withheld shares of common stock to satisfy payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2021 totaled .
11
Warrants
In January 2021, all Class O Warrants and Class M Warrants were exercised under a cashless exercise. The Company withheld shares to satisfy the exercise price and issued shares of common stock.
Warrants outstanding at September
30, 2021, included
Warrants outstanding at September
30, 2020, included
Preferred Stock
At September 30, 2021, there were shares of the
Series B Preferred Stock outstanding with a
At September 30, 2021, there were shares of
the Series C Preferred Stock outstanding with a
In March 2021, shares of the Series C Preferred Stock were converted to shares of common stock at the request of the holder.
In April 2021, shares of the Series B Preferred Stock were converted to shares of common stock at the request of the holder.
In August 2021, shares of the Series C Preferred Stock were converted to shares of common stock at the request of the holders.
During the nine
months ended September 30, 2021 and 2020 dividends paid to holders of the Series C Preferred Stock totaled $
(7) Debt
In December 2013, the Company entered into a promissory
note agreement with its then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $
At September 30, 2021, the principal
balance of the 2013 Promissory Note was $
12
In
April 2018, the Company borrowed $
In April 2019, one of the
prepaid revenue customers requested a refund of the amounts paid. The Company entered into a note agreement to repay $
On December 20, 2019, the Company entered into a promissory note agreement with four of the Company’s major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes the Company to borrow up to $. As of December 31, 2019, the Company had borrowed $ under the 2019 promissory note. In February 2020, the Company borrowed an additional $. The 2019 Promissory Note bears an interest rate of % annually and is due . According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling warrants to purchase shares of the Company’s common stock at $ per share (the Class O Warrants). The fair value of these Class O Warrants issued totaled $ and was recorded as a debt discount and will be amortized over the life of the 2019 Promissory Note. The Company calculated a beneficial conversion feature of $ which will be accreted to interest expense over the life of the 2019 Promissory Note. At September 30, 2021 accrued interest on the 2019 Promissory Note totaled $.
In March 2021, one of the Company’s
subsidiaries, RadQual, entered into a promissory note (the March 2021 Promissory Note) for the purchase of equipment. The principal amount
under the March 2021 Promissory Note totals $
In
April 2021, the Company borrowed $
(8) Commitments and Contingencies
Dependence on Third Parties
The production of High Specific Activity Cobalt is
dependent upon the DOE, and its prime operating contractor, which controls the ATR and laboratory operations at the ATR located outside
of Idaho Falls, Idaho.
13
Sales of our most predominant radiochemical products are dependent upon a few key suppliers. An interruption in production by any of these individual suppliers could have an immediate negative impact upon radiochemical sales until material can be purchased from alternate suppliers including obtaining regulatory approval to use material from alternative suppliers if necessary.
Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual, which in turn has an agreement in place with several companies for distributing the products. The radiochemical product sold by the Company is supplied to the Company through agreements with two suppliers. A loss of any of these customers or suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.
Contingencies
Because all the Company’s business segments
involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained
staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted
within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or
projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would
permit processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this
license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted
money market account held with Merrill Lynch in the amount of $
On May 2, 2019, the Company’s radiological services
team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington.
This work was being performed under a contract with the DOE. The Company supported the initial onsite contamination clean-up operations
at that location and completed removal of the cesium source and Company equipment. On January 5, 2021, the Company was notified by the
DOE that the Company has been indemnified from any financial liability for this event under the Price Anderson Act (PAA). As part of this
indemnification notification, the Company received payment in full for its claim with the DOE for recovery of certain expenses incurred
for this event. The Company recognized Other Income of approximately $
The Company’s corrective actions for this event included termination of all field service activities and removal of these activities from the Company’s NRC license. The Company believes that the loss in revenue resulting from suspension of radiological field service work will be compensated for by increased revenues in the Company’s remaining business segments.
(9) Revenue Recognition
Revenue from Product Sales
The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:
14
| Three Months Ended September 30, 2021 | Three Months Ended September 30, 2020 | |||||||||||||||||||||||||||||||
| U.S. | Outside U.S. | Total Revenues | % of Total Revenues | U.S. | Outside U.S. | Total Revenues | % of Total Revenues | |||||||||||||||||||||||||
| Radiochemical Products | $ | $ | $ | % | $ | $ | $ | % | ||||||||||||||||||||||||
| Cobalt Products | % | % | ||||||||||||||||||||||||||||||
| Nuclear Medicine Products | % | % | ||||||||||||||||||||||||||||||
| Radiological Services | % | % | ||||||||||||||||||||||||||||||
| Fluorine Products | % | % | ||||||||||||||||||||||||||||||
| $ | $ | $ | % | $ | $ | $ | % | |||||||||||||||||||||||||
| Nine Months Ended September 30, 2021 | Nine Months Ended September 30, 2020 | |||||||||||||||||||||||||||||||
| U.S. | Outside U.S. | Total Revenues | % of Total Revenues | U.S. | Outside U.S. | Total Revenues | % of Total Revenues | |||||||||||||||||||||||||
| Radiochemical Products | $ | $ | $ | % | $ | $ | $ | % | ||||||||||||||||||||||||
| Cobalt Products | % | % | ||||||||||||||||||||||||||||||
| Nuclear Medicine Products | % | % | ||||||||||||||||||||||||||||||
| Radiological Services | % | % | ||||||||||||||||||||||||||||||
| Fluorine Products | % | % | ||||||||||||||||||||||||||||||
| $ | $ | $ | % | $ | $ | $ | % | |||||||||||||||||||||||||
The Company’s revenue consists
primarily of calibration and reference standards manufactured for use in the nuclear medicine industry, distribution of radiochemicals
including sodium iodide I-131 drug product, and cobalt source manufacturing. With the exception of certain unique products, the Company’s
normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating
cycle for those products is considered to be two to three years. Accordingly, preliminary payments
received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on
the Company’s condensed consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated
ship dates. For the nine months ended September 30, 2021, the Company reported current unearned revenue of $
Contract Balances
The Company records a receivable when it has an unconditional
right to receive consideration after the performance obligations are satisfied. As of September 30, 2021, and December 31,
2020, accounts receivable totaled $
(10) Leases
The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.
15
| Nine Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Operating lease costs | $ | $ | ||||||
| Short-term operating lease costs | ||||||||
| Financing lease expense: | ||||||||
| Amortization of right-of-use assets | ||||||||
| Interest on lease liabilities | ||||||||
| Total financing lease expense | ||||||||
| Total lease expense | $ | $ | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $ | $ | ||||||
| Right-of-use assets obtained in exchange for new financing lease liabilities | $ | $ | ||||||
| Weighted-average remaining lease term (years) - operating leases | ||||||||
| Weighted-average remaining lease term (years) - financing leases | ||||||||
| Weighted-average discount rate - operating leases | % | % | ||||||
| Weighted-average discount rate - financing leases | % | % | ||||||
The future minimum payments under these operating lease agreements are as follows:
| Operating | Financing | |||||||
| 2021 (excluding the nine months ended September 30, 2021) | $ | $ | ||||||
| 2022 | ||||||||
| 2023 | ||||||||
| 2024 | ||||||||
| 2025 | ||||||||
| Thereafter | ||||||||
| Total minimum operating lease obligations | ||||||||
| Less-amounts representing interest | ( | ) | ( | ) | ||||
| Present value of minimum operating lease obligations | ||||||||
| Current maturities | ( | ) | ( | ) | ||||
| Lease obligations, net of current maturities | $ | $ | ||||||
(11) Segment Information
The Company has
16
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Sale of Product | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Radiological Services | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate revenue | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Depreciation and Amortization | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Radiological Services | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate depreciation and amortization | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Segment Income (Loss) | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Radiological Services | ||||||||||||||||
| Fluorine Products | ( | ) | ( | ) | ( | ) | ||||||||||
| Total Segments | ||||||||||||||||
| Corporate loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net Income | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| Expenditures for Segment Assets | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Radiochemical Products | $ | $ | $ | $ | ||||||||||||
| Cobalt Products | ||||||||||||||||
| Nuclear Medicine Standards | ||||||||||||||||
| Radiological Services | ||||||||||||||||
| Fluorine Products | ||||||||||||||||
| Total Segments | ||||||||||||||||
| Corporate purchases | ||||||||||||||||
| Total Consolidated | $ | $ | $ | $ | ||||||||||||
| September 30, | December 31, | |||||||
| Segment Assets | 2021 | 2020 | ||||||
| Radiochemical Products | $ | $ | ||||||
| Cobalt Products | ||||||||
| Nuclear Medicine Standards | ||||||||
| Radiological Services | ||||||||
| Fluorine Products | ||||||||
| Total Segments | ||||||||
| Corporate assets | ||||||||
| Total Consolidated | $ | $ | ||||||
(12) Subsequent Events
The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined that there were no material items to disclose.
17
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as “anticipates,” “believes,” “should,” “expects,” “future,” “intends” and similar expressions identify forward-looking statements. In particular, statements regarding impact of the COVID-19 outbreak on our business, financial condition, operating results and liquidity, the future prospects of our business segments, future cash flow from operations, the Company’s ability to achieve profitability, the business prospects and growth projection for our business segments, and the status of our proposed uranium de-conversion facility, are forward-looking statements. Forward-looking statements reflect management’s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC) on March 30, 2021 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.
BUSINESS OVERVIEW
International Isotopes Inc., its subsidiaries (including RadQual, LLC) and joint venture, TI Services, LLC (collectively, the Company, we, our, or us) manufacture a full range of nuclear medicine calibration and reference standards, manufacture a range of cobalt products, and distribute sodium iodide I-131 as a generic drug. We own 100% interest of RadQual, LLC (RadQual), a global supplier of molecular imaging quality control and calibration devices.
RADQUAL ACQUISTION
On July 8, 2021, we entered into a Membership Interest Purchase Agreement (the Purchase Agreement) with RadQual and the sellers set forth in the Purchase Agreement, which included our Chairman of the Board, Chief Executive Officer, former Chairman of the Board, and certain other stockholders of the Company (collectively, the Sellers). Pursuant to the Purchase Agreement, we acquired all of the outstanding membership interests of RadQual not then-owned by the Company for an aggregate purchase price of approximately $4.4 million, payable in shares of our common stock valued at $0.11 per share (determined by the average trading price of our common stock on the OTC Markets during the 60 trading day period immediately prior to June 2, 2021) (the RadQual Acquisition). We issued an aggregate of 40,176,236 shares of its common stock to the Sellers as consideration in the RadQual Acquisition. Prior to the RadQual Acquisition, we owned approximately 24.5% of the outstanding membership interests of RadQual, and after acquiring all of the remaining membership interests of RadQual, RadQual became a wholly-owned subsidiary of the Company. The RadQual Acquisition closed on July 8, 2021.
Our business consists of the following five business segments:
Nuclear Medicine Standards. Our Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These sources are used for indication of patient positioning for SPECT imaging, SPECT camera operational testing, and calibration of dose measurement equipment. Revenue from nuclear medicine products includes consolidated sales from TI Services, LLC (TI Services), a 50/50 joint venture that we formed with RadQual in December 2010 to distribute our products, as well as consolidated sales from RadQual. Our nuclear medicine standards products include a host of specially designed items used in the nuclear medicine industry. In addition to the manufacture of these products, we have developed a complete line of specialty packaging for the safe transport and handling of these products.
Cobalt Products. Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. We are the only company in the U.S. that can provide all these unique services. There has been a significant increase in regulation by the Nuclear Regulatory Commission (NRC) in recent years that has created a significant barrier to new entrants into this market. The Company has a contract in place with the U.S. Department of Energy (DOE) for the production of high specific activity cobalt in the Advanced Test Reactor (ATR) in Idaho. This agreement will be in effect until October 2024.
18
Radiochemical Products. Our Radiochemical Products segment includes production and distribution and FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. We are the only U.S. Company distributing this generic drug product. This segment also includes distribution of certain other radiochemical products and contract manufacturing of radiopharmaceutical products for our customers.
Fluorine Products. We established the Fluorine Products segment in 2004 to support production and sale of the gases that we expected to produce using our Fluorine Extraction Process (FEP) in conjunction with the operation of the proposed depleted uranium de-conversion facility in Lea County, New Mexico. Near the end of 2013, due to changes in the nuclear industry, we placed further engineering work on this project on hold. We continue to hold discussions with potential future customers seeking this type of service, however, further development activity within this segment will be deferred until market and industry conditions change to justify resuming design and construction of the facility. In the meantime, the Company expects to continue to incur some costs associated with the maintenance of licenses and other necessary project investments, and to continue to keep certain agreements in place that will support resumption of project activities at the appropriate time.
Radiological Services. Our Radiological Services segment consisted of a wide variety of miscellaneous services such as decommissioning disused irradiation units, performing sealed source exchanges in irradiation and therapy units, and gemstone processing. The Company has suspended all of its field service activities and is in the process of terminating gemstone processing. The Company believes that eliminating work in the Radiological Services segment will allow the Company to better focus upon our core business segments and our new products pipeline. We believe that the loss in revenue resulting from wrapping up of radiological field service work will be more than offset by increased revenues in our remaining business segments.
COVID-19 UPDATE
As a result of the COVID-19 pandemic, we continue to experience a reduction of sales within our nuclear medicine calibration standards segment and radiochemicals segment during the nine-months ended September 30, 2021. There was no discernable impact from COVID-19 to our cobalt products business segment during the period. The decrease in sales for the nine months ended September 30, 2021 for our radiochemical segment was the result of delays in patient treatment. The sale of nuclear medicine reference and calibration standards increased during the nine month period, however, we believe the increase in revenue would have been greater were it not for the continued negative impact of COVID-19 which resulted in the temporary closure of many imaging clinics and suspension of elective or non-essential imaging procedures.
To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. The Company has only seen a limited impact in our raw material supply chain related to the COVID-19, primarily some plastics which have been in strong demand for certain types of PPE. Alternative sources of raw materials have been obtained without any interruption to production. With the heightened concern about corporate liquidity during the COVID-19 pandemic, the Company believes that it has adequate cash to support continuing operations.
RESULTS OF OPERATIONS
Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020
Revenue for the three months ended September 30, 2021 was $2,617,514 as compared to $2,864,288 for the same period in 2020, an overall decrease of $246,774, or approximately 9%. This decrease in revenue was largely the result of decreased revenue in our Radiochemical Products and Cobalt Products segments, as discussed in detail below.
The following table presents a period-to-period comparison of total revenue by segment for the three months ended September 30, 2021 and 2020:
For the three- months ended September 30, | For the three- months ended September 30, | |||||||||||||||
| Sale of Product | 2021 | 2020 | $ change | % change | ||||||||||||
| Radiochemical Products | $ | 1,210,615 | $ | 1,294,546 | $ | (83,931 | ) | -6 | % | |||||||
| Cobalt Products | 408,808 | 544,989 | (136,181 | ) | -25 | % | ||||||||||
| Nuclear Medicine Standards | 973,439 | 958,293 | 15,146 | 2 | % | |||||||||||
| Radiological Services | 16,889 | 54,760 | (37,871 | ) | -69 | % | ||||||||||
| Fluorine Products | 7,763 | 11,700 | (3,937 | ) | -34 | % | ||||||||||
| Total Consolidated | $ | 2,617,514 | $ | 2,864,288 | $ | (246,774 | ) | -9 | % | |||||||
19
Cost of sales increased to $1,006,334 for the three months ended September 30, 2021 from $974,882 for the same period in 2020. This is an increase of $31,452, or approximately 3%. The increase in cost of sales in the three-month comparison was primarily due to the increased raw material cost in our Radiochemical and Cobalt Product segments, as discussed in detail below. Gross profit for the three months ended September 30, 2021 was $1,611,179, compared to $1,889,406 for the same period in 2020. This represents a decrease in gross profit of $278,227, or approximately 15%.
The following table presents cost of sales and gross profit data for each of our business segments for the three months ended September 30, 2021 and 2020:
For the three- months ended September 30, | % of Total Sales | For the three- months ended September 30, | % of Total Sales | |||||||||||||
| 2021 | 2021 | 2020 | 2020 | |||||||||||||
| Total Sales | $ | 2,617,514 | $ | 2,864,288 | ||||||||||||
| Cost of Sales | ||||||||||||||||
| Radiochemical Products | $ | 459,344 | 17 | % | $ | 447,174 | 16 | % | ||||||||
| Cobalt Products | 148,855 | 6 | % | 126,677 | 4 | % | ||||||||||
| Nuclear Medicine Standards | 398,112 | 15 | % | 395,148 | 14 | % | ||||||||||
| Radiological Services | 23 | 0 | % | 5,883 | 0 | % | ||||||||||
| Fluorine Products | — | 0 | % | — | — | |||||||||||
| Total Segments | 1,006,334 | 38 | % | 974,882 | 34 | % | ||||||||||
| Gross Profit | $ | 1,611,180 | $ | 1,889,406 | ||||||||||||
| Gross Profit % | 62 | % | 66 | % | ||||||||||||
Operating expense increased approximately 15% to $1,609,758 for the three months ended September 30, 2021, from $1,399,392 for the same period in 2020. This increase of $210,366, is primarily due to an approximate 30% increase in General, Administrative, and Consulting costs. This increase in mainly due to increased costs for licenses and depreciation.
The following table presents a comparison of total operating expense for the three months ended September 30, 2021 and 2020:
For the three- months ended September 30, | For the three- months ended September 30, | |||||||||||||||
| Operating Costs and Expenses: | 2021 | 2020 | % change | $ change | ||||||||||||
| Salaries and Contract Labor | $ | 650,065 | $ | 662,821 | -2 | % | $ | (12,756 | ) | |||||||
| General, Administrative and Consulting | 885,807 | 679,520 | 30 | % | 206,287 | |||||||||||
| Research and Development | 73,886 | 57,051 | 30 | % | 16,835 | |||||||||||
| Total operating expenses | $ | 1,609,758 | $ | 1,399,392 | 15 | % | $ | 210,366 | ||||||||
Other income was $54,083 for the three months ended September 30, 2021, as compared to Other Income of $95,503 for the same period in 2020. This is a decrease of $41,420. The decrease is due to income from the SBA Loan (as defined below) of $50,600 converted to grant income during the three months ended September 30, 2020. Interest expense for the three months ended September 30, 2021 was $191,544, compared to $193,085 for the same period in 2020. This is an decrease of $1,541, or approximately 1%. Interest expense includes dividends accrued on our Series C Redeemable Convertible Preferred Stock (Series C Preferred Stock). For the three months ended September 30, 2021, we accrued dividends payable of $57,620, which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $34,400 was recorded for this same period for the issuance of warrants related to the preferred stock issuances. See Note 7 “Debt” to our unaudited condensed consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.
Our net loss for the three months ended September 30, 2021, was ($136,869), compared to net income of $307,050, for the same period in 2020. This is a decrease of income of $443,919 is the result of increased cost of sales and operating expenses in the three months ended September 30, 2021 as compared to the same period in 2020.
Radiochemical Products. Revenue from the sale of radiochemical products for the three months ended September 30, 2021 was $1,210,615, compared to $1,294,546 for the same period in 2020. This is a decrease of $83,931, or approximately 6%. The decrease is a result of a reduction in payments received for contract manufacturing services in the 2021 three-month period compared to 2020.
20
Gross profit of radiochemical products for the three months ended September 30, 2021 was $751,271, compared to $847,372, for the same period in 2020, and gross profit percentages were approximately 62% and 65% for the three months ended September 30, 2021 and 2020, respectively. This decreased gross profit percentage is a result of increased cost of raw materials. Cost of sales for radiochemical products increased to $459,344 for the three months ended September 30, 2021, as compared to $447,174 for the same period in 2020. This is an increase of $12,170, or approximately 3%, and was primarily the result of increased cost of raw material. Operating expense for this segment increased to $380,684 for the three months ended September 30, 2021, compared to $304,559 for the same period in 2020. This increase in operating expense of $76,125, or approximately 25%, is primarily due to increased costs for licenses and permits related to our FDA approved radiopharmaceutical product. This segment reported net income of $370,586 for the three months ended September 30, 2021, as compared to net income of $542,814 for the same period in 2020. The decrease in net income of $172,228 or approximately 32%, is primarily the result of the increased cost of sales and operating expenses during the three months ended September 30, 2021.
Cobalt Products. Revenue from the sale of cobalt products for the three months ended September 30, 2021 was $408,808, compared to $544,989, for the same period in 2020. This represents an decrease of $136,181, or approximately 25%. The decrease is due to timing of cobalt demand and our ability to procure material for this demand. The decrease is also due to recognition of income for cobalt provided under our cobalt-60 supply agreements as described below.
In October 2014, we entered into a ten-year agreement with the DOE for the irradiation of cobalt targets. The agreement gives us the ability to purchase the current full capacity of the DOE’s ATR throughout the ten-year period. It takes many years to irradiate these cobalt targets to the desired level of activity. Production calculations indicated we should have been able to anticipate having high specific activity cobalt available for our customers in late 2019. However, extended reactor shutdowns and lower than expected production rates of cobalt-60 in the new design cobalt targets delayed delivery of high specific activity cobalt until May 2021. Future delivery dates of high activity cobalt are uncertain at present. However, the Company has been able to acquire additional cobalt material from the DOE in lower activity ranges to satisfy some customers’ needs.
During 2015, we entered into cobalt-60 supply agreements with several customers. The terms of the agreements required pre-payments to secure cobalt material in future years. Those prepayments were recorded as unearned revenue on our condensed consolidated balance sheet.
Cost of sales for the three months ended September 30, 2021, was $148,855, as compared to $126,677, for the same period in 2020. Gross profit for cobalt products for the three months ended September 30, 2021, was $259,953 compared to $418,312 for the same period in 2020. This is a decrease of $158,359, or approximately 38% and is primarily attributable to reduced sales for the three months ended September 30, 2020, as compared to the same period in 2020. Operating expense in this segment increased to $93,145 for the three months ended September 30, 2021, from $75,588 for the same period in 2020. This is an increase of $17,557, or approximately 23%. This increase in operating expenses for the three months ended September 30, 2021 is due to increased support labor from increased shipment activity. Our net income for cobalt products was $166,808 for the three months ended September 30, 2021, as compared to a net income of $342,724 for the same period in 2020. The decrease in net income of $175,916, or approximately 51%, was attributable to timing of cobalt demand and our ability to procure material for this demand.
Nuclear Medicine Standards. Revenue from nuclear medicine products for the three months ended September 30, 2021, was $973,439, compared to $958,293 for the same period in 2020. This represents an increase in revenue of $15,146, or approximately 2%. As discussed above, due to a change in the ownership of RadQual, in August 2017 we began reporting our investment in RadQual on a consolidated basis. In July 2021, we acquired all remaining interest in RadQual. Therefore, revenue in this segment includes all sales of RadQual and TI Services with all intercompany sales for the consolidated period eliminated. The increase in sales for the period ended September 30, 2021 was due to increased order activity as recovery from the COVID-19 pandemic continues.
Cost of sales for our nuclear medicine standards segment for the three months ended September 30, 2021, was $398,112, as compared to $395,148 for the same period in 2020. The increase in cost of sales in the period-to-period comparison of $2,964, or 1%, is due to increased sales for the three-month period ended September 2021, as compared to the same period in 2020. Gross profit for our nuclear medicine standards segment for the three months ended September 30, 2021 was $575,327 compared to $563,145 for the same period in 2020. This is an increase in gross profit of $12,182, or approximately 2%. The increase in gross profit in the period-to-period comparison is primarily the result of the increased sales. Our gross profit percentages were approximately 59% and 59% for the three-month periods ended September 30, 2021 and 2020, respectively.
21
Operating expense for this segment for the three months ended September 30, 2021 increased to $454,875, from $432,648 for the same period in 2020. This is an increase of $22,227, or approximately 5%, and is the result of increased expenses for production supplies, support labor expenses, and operating expenses related to RadQual as compared to the same period in 2020. Operating expense includes consolidated net operating expense reported for RadQual of $143,480 and non-controlling member interest expense of $7,812, for the three months ended September 30, 2021, as compared to $136,661 of net operating expense and non-controlling member interest expense of $63,309 for the same period in 2020. The decrease in non-controlling member interest expense was due to our purchase of all remaining interest in RadQual in July 2021. Net operating expense included for TI Services was $22,048 for the three months ended September 30, 2021, and $22,486 for the same period in 2020. TI Services non-controlling interest included was ($3,537) for the three-month period ended September 30, 2021, as compared to $22,154 for the same period in 2020. Other income for this segment for the three months ended September 30, 2021 was $0 as compared to $50,600 of other income from a TI Services SBA Loan converted to grant income for the three months ended September 30, 2020. Net income for this segment for the three months ended September 30, 2021 was $120,452, compared to $181,097 for the same period in 2020. This is a decrease in net income of $60,645, or approximately 33% and is a result of other income of $50,600 in 2020 as compared to $0 in 2021.
Radiological Services. Revenue from all radiological services for the three months ended September 30, 2021 was $16,889, compared to $54,760, for the same period in 2020, a decrease of $37,871 or approximately 69%. The decrease in the revenue for the period comparison is the result of decreased gemstone processing activity from the wrapping up of this contract work.
On May 2, 2019, our radiological services team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington. This work was being performed under a contract with the DOE. Beginning in August 2019, the DOE assumed full control of the cleanup operations and assumed all the financial obligations associated with the contractors hired to carry out all remaining facility recovery operations. On January 5, 2021, we were notified by the DOE that we have been indemnified from any financial liability for this event under the Price Anderson Act (PAA). We also have reached a final settlement with our insurance company regarding this claim.
In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service will continue throughout 2021 and the Company expects to see a steady decline in revenue from this service as production is wrapped up. We plan to convert the spaces in the facility that had been used to perform this contract work into expanded Nuclear Medicine product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.
Cost of sales for the three months ended September 30, 2021, was $23, as compared to $5,883, for the same period in 2020. Gross profit for this segment for the three months ended September 30, 2021 was $16,866, compared to $48,877, reported for the same period in 2020. The decrease in gross profit of $32,011, or approximately 65%, is the result of decreased activity of gemstone processing for the three months ended September 30, 2021, as compared to the same period in 2020. We expect our costs of sales to continue to be very low going forward. Operating expense for the three months ended September 30, 2021 was $4,133 as compared to $14,731, reported for the same period in 2020. This decrease of $10,598, or approximately 72%, is the result of decreased sales and activity within the business segment.
Net income for this segment for the three months ended September 30, 2021 was $12,733, compared to net income of $34,145, for the same period in 2020. This is a decrease in net income of $21,412 is the result of decreased sales and activity within the business segment.
Fluorine Products. For the three months ended September 30, 2021, we had revenues related to Fluorine Products of $7,763 as compared to $11,700 for the same period in 2020. These revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. During the three months ended September 30, 2021, we incurred $34,348 of expense related to items in support of future planning and design for the proposed de-conversion facility, as compared to $38,340 for the same three-month period in 2020. This is a decrease of 10% in the period-to-period comparison.
We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our fluorine extraction process (FEP). The project has been placed on hold since 2013 and we will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials until such time that we decide to resume the project.
22
Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020
Revenue for the nine-month period ended September 30, 2021 was $7,369,922, as compared to $7,359,633 for the same period in 2020, an increase of $10,289, or less than 1%. This increase in revenue was largely the result of increased revenue in our Cobalt Products and Nuclear Medicine Standards segments partially offset by decreases in revenue in our Radiochemical, Radiological Services and Fluorine Products segment, as discussed in detail below.
The following table presents a period-to-period comparison of total revenue by segment for the nine months ended September 30, 2021 and September 30, 2020:
For the nine- months ended September 30, | For the nine- months ended September 30, | |||||||||||||||
| Sale of Product | 2021 | 2020 | $ change | % change | ||||||||||||
| Radiochemical Products | $ | 3,100,001 | $ | 3,162,820 | $ | (62,819 | ) | -2 | % | |||||||
| Cobalt Products | 1,104,176 | 1,075,275 | 28,901 | 3 | % | |||||||||||
| Nuclear Medicine Standards | 2,988,326 | 2,778,290 | 210,036 | 8 | % | |||||||||||
| Radiological Services | 147,644 | 171,048 | (23,404 | ) | -14 | % | ||||||||||
| Fluorine Products | 29,775 | 172,200 | (142,425 | ) | -83 | % | ||||||||||
| Total Consolidated | $ | 7,369,922 | $ | 7,359,633 | $ | 10,289 | 0 | % | ||||||||
Gross profit for the nine-month period ended September 30, 2021 was $4,360,266, compared to $4,512,317, for the same period in 2020. This represents a decrease of $152,051 or approximately 3%. This decrease in gross profit was largely the result of decreased revenue in our Radiochemical Products and Fluorine Products segment partially offset by an increase in revenue in our Nuclear Medicine Standards and Cobalt Products segments, as discussed in detail below.
The following table presents cost of sales and gross profit data for each of our business segments for the nine months ended September 30, 2021 and 2020:
For the nine- months ended September 30, | % of Total Sales | For the nine- months ended September 30, | % of Total Sales | |||||||||||||
| 2021 | 2021 | 2020 | 2020 | |||||||||||||
| Total Sales | $ | 7,369,922 | $ | 7,359,633 | ||||||||||||
| Cost of Sales | ||||||||||||||||
| Radiochemical Products | $ | 1,251,953 | 17 | % | $ | 1,337,586 | 18 | % | ||||||||
| Cobalt Products | 456,056 | 6 | % | 270,207 | 4 | % | ||||||||||
| Nuclear Medicine Standards | 1,301,279 | 18 | % | 1,200,302 | 16 | % | ||||||||||
| Radiological Services | 368 | 0 | % | 39,221 | 1 | % | ||||||||||
| Fluorine Products | — | 0 | % | — | 0 | % | ||||||||||
| Total Segments | 3,009,656 | 41 | % | 2,847,316 | 39 | % | ||||||||||
| Gross Profit | $ | 4,360,266 | $ | 4,512,317 | ||||||||||||
| Gross Profit % | 59 | % | 61 | % | ||||||||||||
Operating expenses were $4,794,650 for the nine-month period ended September 30, 2021, compared to $4,327,714 for the same period in 2020. This represents an increase of $466,936, or approximately 11%. This increase is primarily due to an approximate 31% increase in General, Administrative and Consulting costs partially offset by an approximate 9% decrease in Salaries and Contract Labor costs. The increase in General, Administrative and Consulting costs is a result of increased license and permits costs and increased depreciation expenses during the nine months ended September 30, 2021, as compared to the same period in 2020. Research and Development costs increased to $183,102, for the nine months ended September 30, 2021, as compared to $145,444, for the same period in 2020. This is an increase of $37,658, or approximately 26% and is primarily the result of a decrease in expenditures for product development in several of our business segments for the nine months ended September 30, 2021, as compared to the same period in 2020.
23
The following table shows total operating expenses for the nine-month period ended September 30, 2021 and 2020:
For the nine- months ended September 30, | For the nine- months ended September 30, | |||||||||||||||
| Operating Costs and Expenses: | 2021 | 2020 | % change | $ change | ||||||||||||
| Salaries and Contract Labor | $ | 1,944,013 | $ | 2,140,565 | -9 | % | $ | (196,552 | ) | |||||||
| General, Administrative and Consulting | 2,667,535 | 2,041,705 | 31 | % | 625,830 | |||||||||||
| Research and Development | 183,102 | 145,444 | 26 | % | 37,658 | |||||||||||
| Total operating expenses | $ | 4,794,650 | $ | 4,327,714 | 11 | % | $ | 466,936 | ||||||||
Other income was $229,559 for the nine months ended September 30, 2021, as compared to other income of $679,216 for the same period in 2020. This is a decrease in income of $449,657. The decrease is primarily due to income from the SBA Loan converted to grant income of $546,100 during the nine months ended September 30, 2020.
Interest expense for the nine months ended September 30, 2021 was $601,291, compared to $584,309 for the same period in 2020. This is an increase of $16,982, or approximately 3%. Interest expense includes dividends accrued on our Series C Preferred Stock. As discussed below, we issued Series C Preferred Stock in February and May 2017. For the nine months ended September 30, 2021, we accrued dividends payable of $184,010 which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $99,318 was recorded for this same period for the issuance of warrants related to the preferred stock issuances. Additionally, non-cash interest expense in the amount of $192,199 for the issuance of warrants in conjunction with the 2019 Promissory Note was recorded for the nine months ended September 30, 2021.
Our net loss for the nine-month period ended September 30, 2021, was ($919,408) as compared to net income of $113,884 for the same period in 2020. This is a decrease in income of $1,033,292 or approximately 907%. This decrease in net income is a result of decreased gross profit and increased operating expenses combined with income from the SBA Loan converted to grant income of $546,100 during the nine months ended September 30, 2020 compared to $0 for the same period in 2021.
Radiochemical Products. Revenue from the sale of radiochemical products for the nine-month period ended September 30, 2021 was $3,100,001 compared to $3,162,820 for the same period in 2020. This is a decrease of $62,819, or approximately 2%. The decrease is a result of a reduction in payments received for contract manufacturing services in the 2021 nine-month period compared to 2020.
Cost of sales was $1,251,953 for the nine-month period ended September 30, 2021, and $1,337,586 for the same period in 2020. This is a decrease of $85,633, or approximately 6%. This decrease is primarily the result of shift of sales activity to our new generic sodium iodide I-131 drug product which has a higher profit margin.
Gross profit percentages for our radiochemical products for the nine months ended September 30, 2021 and 2020 were approximately 60% and 58%, respectively. Operating expense for this segment for the nine-month period ended September 30, 2021 was $1,068,580, compared to $880,419 for the same period in 2020. This is an increase of $188,161, or approximately 21%, and is primarily due to increased costs for licenses and depreciation partially offset by decreased expenses for support labor. Net income for this segment increased to $779,468 for the nine-month period ended September 30, 2021, from $929,162 for the same period in 2020. This decrease of $149,694, or approximately 16%, is primarily the result of a reduction in payments received for contract manufacturing during the nine months ended September 30, 2021.
Cobalt Products. Revenues from the sale of cobalt products for the nine-month period ended September 30, 2021 were $1,104,176, compared to $1,075,275 for the same period in 2020. This is an increase of $28,901, or approximately 3%, and is the result of increased income from cobalt recycling.
During 2015, we entered into cobalt-60 supply agreements with several customers. The terms of the agreements required pre-payments to secure cobalt material in future years. Those prepayments were recorded as unearned revenue on our condensed consolidated balance sheet.
Cost of sales for the nine months ended September 30, 2021, was $456,056, as compared to $270,207, for the same period in 2020. Gross profit for cobalt products for the six months ended September 30, 2021 was $648,120 compared to $805,068 for the same period in 2020. This is a decrease of $156,948, or approximately 20%. Our gross profit percentages were approximately 59% and 75% for the nine-month periods ended September 30, 2021 and 2020, respectively. The decrease in the gross profit percentage for the nine months ended June 30, 2021 is primarily due to increased costs of raw material used in the manufacture of sealed sources. Operating expense in this segment increased to $302,828 for the nine months ended September 30, 2021, from $262,673 for the same period in 2020. This is an increase of $40,155, or approximately 15% is a result of increased equipment expenses in the nine months ended September 30, 2021 as compared to the same period in 2020. Our net income for cobalt products was $345,292 for the nine months ended September 30, 2021, as compared to a net income of $542,394 for the same period in 2020. The decrease in net income of
24
$197,102 or approximately 36%, was attributable to the increase in operating expenses for the nine months ended September 30, 2021, as compared to the same period in 2020.
Nuclear Medicine Standards. Revenue from nuclear medicine products for the nine-month period ended September 30, 2021 was $2,988,326 compared to $2,778,290 for the same period in 2020. This represents an increase in revenue attributable to this segment of $210,036, or approximately 8%. The increase in sales for the period ended September 30, 2021 was due to increased order activity and sales of some new products as recovery from the Covid-19 pandemic continues. As discussed above, due to a change in the ownership of RadQual, in August 2017 we began reporting our investment in RadQual on a consolidated basis. In July 2021, we acquired all remaining interest in RadQual. Therefore, revenue in this segment includes all sales of RadQual and TI Services with all intercompany sales for the consolidated period eliminated.
Gross profit for the nine-month period ended September 30, 2021 was $1,687,047, as compared to $1,577,988 for the same period in 2019, a decrease of $109,059, or approximately 7%. Operating expense for this segment for the nine-month period ended September 30, 2021 increased to $1,303,841, from $1,145,134 for the same period in 2020. This is an increase of $158,707 or approximately 14% and includes consolidated net operating expense reported for RadQual of $448,381 and non-controlling member interest expense of $116,765, for the nine months ended September 30, 2021, compared to consolidated net operating expense of $414,849 and non-controlling member interest expense of $145,533, for the nine months ended September 30, 2020. Other Income for the nine months ended September 30, 2021, was $0. For the nine months ended September 30, 2020, Other Income for this segment included $50,600 of income from a TI Services SBA Loan converted to grant income. Net income for this segment for the nine-month period ended September 30, 2021, decreased to $383,207, approximately 21%, from $483,454 for the same nine-month period in 2020.
Radiological Services. Revenue from all radiological services for the nine months ended September 30, 2021 was $147,644, compared to $171,048, for the same period in 2020, a decrease of $23,404 or approximately 14%. The decrease in the revenue for the period comparison is the result of decreased gemstone processing activity.
On May 2, 2019, our radiological services team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington. On January 5, 2021, we were notified by the DOE that we have been indemnified from any financial liability for this event under the Price Anderson Act (PAA). As part of this indemnification notification, we received payment in full for our claim with the DOE for recovery of certain expenses incurred for this event. We recognized Other Income of approximately $150,000 in the six months ended June 30, 2021 for additional cost recoveries for this event. All remaining cost recoveries as part of this settlement with the DOE were recognized in previous financial periods pursuant to ASC 410-30. These funds were used to pay all outstanding subcontractors and reimburse our insurance company for payments they previous paid us for this matter. In October 2021, we reached a final settlement with our insurance company regarding this claim.
Cost of sales for the nine months ended September 30, 2021, was $368, as compared to $39,221, for the same period in 2020. Gross profit for this segment for the nine months ended September 30, 2021 was $147,276, compared to $131,827, reported for the same period in 2020. The increase in gross profit of $15,449, or approximately 12%, is the result of decreased costs for gemstone processing for the nine months ended September 30, 2021, as compared to the same period in 2020. Operating expense for the nine months ended September 30, 2021 was $23,893 as compared to $126,142, reported for the same period in 2020. This decrease of $102,249, or approximately 81%, is the result of decreased sales and activity within the business segment.
Net income for this segment for the nine months ended September 30, 2021 was $123,383, compared to net loss of $5,684, for the same period in 2020. This is an increase in net income of $117,699 and is the result in the increase in gross profit and decreased operating expenses for the same period in 2020.
Fluorine Products. For the nine months ended September 30, 2021, we had revenues related to Fluorine Products of $29,775 compared to $172,200, for the same period in 2020, a decrease of $142,425 or approximately 83%. These revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. During the nine months ended September 30, 2021, we incurred $121,500 of expense related to items in support of future planning and design for the proposed de-conversion facility, as compared to $112,430 for the same nine-month period in 2020. This is an increase of 8% in the period-to-period comparison.
We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our Fluorine Extraction Process (“FEP”). We will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials.
25
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2021, we had cash and cash equivalents of $753,526 as compared to $1,113,032 at December 31, 2020. This is a decrease of $359,506 or approximately 32%. For the nine months ended September 30, 2021, net cash provided in operating activities was $64,294 and net cash provided for the nine months ended September 30, 2020 in operating activities was $960,314. The decrease in cash provided in operating activities and decrease in cash and cash equivalents at period end in the period-to-period comparison is the result of increased net loss and decreased accounts payable.
Inventories at September 30, 2021 totaled $582,298, and inventories at December 31, 2020 totaled $837,787. Previously, a significant amount of our inventory consisted of work-in-process cobalt raw material held at the ATR located outside of Idaho Falls, Idaho. Work in process includes costs to irradiate cobalt-60 material under a contract with the DOE. This material has been placed in the ATR and the Company made progress payments to purchase this material which was completed during the second quarter of 2021. At September 30, 2021, this raw cobalt material inventory at the ATR accounted for approximately 0% of our work-in-process inventory. At December 31, 2020, this in-process raw material inventory accounted for approximately 46% of our work in process inventory.
Cash used in investing activities was $196,730 for the nine months ended September 30, 2021, and cash provided in investing activities was $1,756 for the same period in 2020. The cash used in the nine months ended September 30, 2021 was for the purchase of equipment.
Financing activities used cash of $34,994, during the nine months ended September 30, 2021, and cash used by financing activities for the same period in 2020 was $636,136. During the nine months ended September 30, 2021, cash paid for interest was $69,042 and during the same six-month period in 2020, cash paid for interest was $67,575. Additionally, during the nine months ended September 30, 2021, we received $13,528 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan, as compared to $13,430 for the same period in 2020.
In February 2021, the Company paid its third annual dividend on the Series C Preferred Stock. Dividends payable totaled $254,280. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 1,398,200 shares of common stock in lieu of a dividend payment of $207,480. The remaining $46,800 of dividend payable was settled with cash.
Total decrease in cash for the nine-month period ended September 30, 2021, was $167,430 compared to a cash increase of $325,934 for the same period in 2020.
We expect that cash from operations, cash raised via equity or debt financings, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, our ability to raise additional capital and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all, especially in light of the market volatility and uncertainty as a result of the COVID-19 pandemic.
At September 30, 2021, there were 7,065,000 outstanding warrants to purchase our common stock. Included in this number are 4,140,000 Class M Warrants issued February 17, 2017, with an exercise price of $0.12 per share and an expiration date of February 17, 2022; and, 2,925,000 Class N Warrants issued May 12, 2017, with an exercise price of $0.10 per share and an expiration date of May 12, 2022.
Debt
In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017 and each lender was granted an additional 7,500,000 Class L warrants to purchases shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged. At September 30, 2021, accrued interest payable on the 2013 Promissory Note totaled $234,234.
26
In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged. At September 30, 2021, accrued interest on the 2018 Promissory Note totaled $24,770.
In December 2019, we entered into a promissory note agreement with our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes us to borrow up to $1,000,000. As of December 31, 2019, we had borrowed $675,000 under the 2019 promissory note. In February 2020, we borrowed an additional $325,000. The 2019 Promissory Note is secured and bears interest at 4% per annum and has a maturity date of December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, a holder of the 2019 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. In connection with the 2019 Promissory Note, we issued 30,000,000 Class O Warrants to purchase shares of our common stock at $0.045 per share (the Class O Warrants). The Class O Warrants were exercisable at an exercise price of $0.045 per share and had a term of five years. In January 2021, all 30,000,000 Class O Warrants were exercised. At September 30, 2021, accrued interest on the 2019 Promissory Note totaled $69,131.
In March 2021, one of the Company’s subsidiaries, RadQual, entered into a promissory note (the March 2021 Promissory Note) for the purchase of equipment. The principal amount under the March 2021 Promissory Note totals $101,250, bears interest at 5%, is secured by equipment, and is due March 2023.
In April 2021, we borrowed $250,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the April 2021 Promissory Note). The April 2021 Promissory Note bears an interest rate of 6% annually and is due December 31, 2022. At any time, the holder of the April 2021 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based at the price of $0.11 per share. At September 30, 2021 accrued interest on the April 2021 Promissory Note totaled $7,000.
On April 23, 2020, we, through our wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). We received total proceeds of $546,100 from this SBA Loan. The SBA Loan was scheduled to mature on April 22, 2022 and had a 1.00% interest rate and was subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act.
In July 2021, we received notification from the SBA that we received approval of forgiveness of the entire loan.
OFF-BALANCE SHEET ARRANGEMENTS
As of September 30, 2021, we had no off-balance sheet arrangements or obligations.
CRITICAL ACCOUNTING POLICIES
From time-to-time, management reviews and evaluates certain accounting policies that are considered to be significant in determining our results of operations and financial position.
A description of the Company’s critical accounting policies that affect the preparation of the Company’s financial statements is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 30, 2021.
27
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of June 30, 2021, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2021.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A discussion of legal matters is found in Note 8, “Commitments and Contingencies”, in the accompanying notes to the unaudited condensed consolidated financial statements included in Part I - Item 1. Financial Statements of this Quarterly Report.
ITEM 1A. RISK FACTORS
There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020.
28
ITEM 6. EXHIBITS
Exhibit No. | Description |
| 2.1 | Membership Interest Purchase Agreement, dated July 8, 2021, between RadQual, LLC, International Isotopes Inc., and each of the sellers named therein. |
| 3.1 | Restated Certificate of Formation, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q for quarter ended June 30, 2010). |
| 3.2 | Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 24, 2017). |
| 3.3 | Bylaws (incorporated by reference to Exhibit 3.2 of the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)). |
| 31.1 | Certification by the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 31.2 | Certification by the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.* |
| 32.1 | Certification by the Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |
| 32.2 | Certification by the Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |
| 101 | The following financial statements, formatted in XBRL: (i) Unaudited Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020, (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* |
_______________
* Filed herewith.
** Furnished herewith.
† Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules to the Securities and Exchange Commission.
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 12, 2021 | International Isotopes Inc. | |
| By: | /s/ Steve T. Laflin | |
| Steve T. Laflin | ||
| President and Chief Executive Officer | ||
| By: | /s/ W. Matthew Cox | |
| W. Matthew Cox | ||
| Chief Financial Officer | ||
30